Najlepsi lekarze do leczenia gruczolakoraka w Izraelu – TOP 21 lekarz

Kierownik Oddziału Onkologii Tkanek Miękkich i Kości w Centrum Medycznym Sourasky – dr Merimsky specjalizuje się w leczeniu złożonych przypadków mięsaków.

• Ponad 25 lat doświadczenia w onkologii ortopedycznej
• Odbył staż specjalistyczny w Institut Gustave Roussy w Paryżu
• Członek sekcji mięsaków ESMO oraz IASLC
• Publikuje liczne prace naukowe na temat nowotworów złośliwych kości i tkanek miękkich

Dr Pelles Sharon specjalizuje się w zaawansowanych metodach leczenia gruczolakoraka w Centrum Medycznym Sourasky, w tym w chemioterapii HIPEC i immunoterapii.

• Ekspert w zakresie dootrzewnowej chemioterapii perfazyjnej w warunkach hipertermii (HIPEC) w leczeniu nowotworów jamy brzusznej
• Zapewnia spersonalizowane protokoły immunoterapii, w tym leczenie preparatem Keytruda
• Prowadzi badania kliniczne dotyczące postaw pacjentów wobec testów onkologicznych
• Wykonuje złożone operacje metodą Whipple’a w przypadku gruczolakoraka trzustki

Dr Sarid specjalizuje się w chemioterapii i radioterapii, posiadając ponad 25-letnie doświadczenie onkologiczne zdobyte w czołowym izraelskim Centrum Medycznym Sourasky (Ichilov).

• Ukończyła studia na Uniwersytecie Oksfordzkim w zakresie urologii onkologicznej
• Pełni funkcję głównego badacza w badaniach klinicznych nad terapiami przeciwnowotworowymi
• Jest autorką ponad 30 artykułów na temat leczenia nowotworów
• Jest członkiem ESMO, ASCO oraz izraelskich towarzystw onkologicznych

Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.

He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.

He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.

Prof. Ido Nachmany heads the Second Surgical Department at Sheba Medical Center. He specializes in HPB and robotic surgery for diseases of the liver, pancreas, and bile ducts, and for gastrointestinal neuroendocrine tumors. He also performs adrenal, spleen, and stomach surgery. Forbes listed him among Israel’s top physicians.

He advances minimally invasive robotic and laparoscopic techniques. The aim is better precision and faster recovery.

Credentials: Senior Lecturer at Tel Aviv University. Member of ASTS and IHPBA. Completed HPB and abdominal transplant fellowships at the Thomas E. Starzl Transplantation Institute. Board certified in General Surgery (Israel), Abdominal Organ Transplantation (ASTS), and HPB Surgery (University of Pittsburgh). He has published in Cancer Research, the Journal of the American College of Surgeons, and the European Journal of Surgical Oncology.

Dr. Shira Felder is a senior radiation oncologist. She focuses on gynecologic and urologic cancers. She has advanced expertise in VMAT, IMRT, SBRT, and gynecologic brachytherapy. She delivers precise treatment with fewer side effects.

She heads the Gynecologic Oncology Service at Sheba Medical Center. She is a senior physician in the Radiation Oncology Division. She earned her MD at Hadassah. She completed residency at Sheba and a fellowship in the Radiation Medicine Program at the University of Toronto and Princess Margaret Cancer Centre. She is board-certified in Radiation Oncology. She is a member of ESTRO, the Israeli oncology societies, the CPSO, and the CMA.

Her research covers brachytherapy patient safety. It also includes stereotactic ablative radiotherapy for stage I lung cancer. She has studied treatment delays in cervical cancer. She has examined vitamin D deficiency in oncology patients.

Dr. Almog Ben-Yaacov is an Attending Surgeon in the Department of General and Oncological Surgery (Surgery C) at Sheba Medical Center. He specializes in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). His clinical focus includes gastric cancer, sarcoma, and complex colorectal malignancies. Since 2018, he has performed more than 200 HIPEC procedures.

MD, Semmelweis University, 2006, with honors. Training in cardiothoracic surgery at Sheba Medical Center. Residency in general surgery at Montefiore (Albert Einstein) and at Rabin (Beilinson). Board-certified in General Surgery and in Surgical Oncology.

Advanced training includes ESSO-certified HIPEC in Hamburg. Microwave liver ablation in Reims. NanoKnife at King’s College London. Advanced surgical oncology at Memorial Sloan Kettering (2019). His publications cover CRS+HIPEC outcomes and Hartmann’s reversal.

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Profesor Ido Wolf kieruje oddziałem onkologii klinicznej w czołowym centrum medycznym Sourasky w Tel Awiwie i udziela konsultacji w celu uzyskania drugiej opinii medycznej.

• Specjalizuje się w udzielaniu drugiej opinii medycznej
• Odbył liczne szkolenia w centrum medycznym Sheba oraz centrum medycznym Cedars-Sinai
• Posiada stopień doktora i prowadzi działalność dydaktyczną na Uniwersytecie w Tel Awiwie
• Należy do ASCO, AACR oraz innych prestiżowych międzynarodowych organizacji onkologicznych

Dr Raphael kieruje izraelską narodową inicjatywą medycyny genomicznej w onkologii i inicjuje badania kliniczne nad immunoterapią NDRP.

• Starszy wykładowca na Wydziale Nauk Medycznych Uniwersytetu w Tel Awiwie
• Główny badacz w licznych badaniach klinicznych nad immunoterapią NDRP
• Moderator Molekularnego Konsylium Onkologicznego Izraelskiego Towarzystwa Raka Płuc
• Specjalizuje się w profilowaniu genomicznym i technikach płynnej biopsji
• Członek stowarzyszeń ESMO oraz IASLC

Kieruje Oddziałem Chirurgii Kolorektalnej w Centrum Medycznym Sourasky (Ichilov). Jest ekspertem w zakresie technik otwartych oraz małoinwazyjnych.

• Posiada ponad 20-letnie doświadczenie chirurgiczne
• Wybitny specjalista w wykonywaniu złożonej procedury Whipple’a
• Chirurg jamy brzusznej koncentrujący się na chirurgii onkologicznej

Dyrektor oddziału hospitalizacji onkologicznej w Ichilov, jednym z czołowych szpitali w Izraelu. Od 2005 roku uczestniczy w zaawansowanych badaniach klinicznych.

• Posiada ponad 20-letnie doświadczenie kliniczne w dziedzinie onkologii i chorób wewnętrznych
• Prowadzi badania pierwotne i wtórne w ramach badań onkologicznych fazy I, II i III
• Posiada licencję na wykonywanie zawodu lekarza w Izraelu od stycznia 2000 roku
• Ukończył specjalistyczny staż w dziedzinie onkologii w Centrum Medycznym w Tel Awiwie

Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.

He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.

His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.

He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Zohar Dotan is Head of the Urology Department at Sheba Medical Center. He is a leading uro-oncologist and a pioneer of robotic and laparoscopic urologic surgery in Israel.

He has authored more than 50 scientific publications. He is a regular speaker at international conferences. He has received awards from the American Association of Clinical Surgery, including recognition for research in prostate cancer treatment.

Leadership and credentials: Head of the Israeli Uro-Oncology Society. Assistant Professor at Tel Aviv University. Member of the Israeli, American, and European Urological Associations. Training: MD from Tel Aviv University and a PhD in Genetics. Urology residency at Sheba Medical Center. Fellowship in uro-oncology and laparoscopic surgery at Memorial Sloan Kettering, New York.

Kieruje całym Centrum Onkologii jako lekarz naczelny w Centrum Medycznym Assuta.

• Specjalizuje się w onkologii klinicznej i leczeniu nowotworów
• Posiada bogate doświadczenie w prowadzeniu złożonych przypadków onkologicznych
• Nadzoruje opiekę nad pacjentami i protokoły medyczne w wiodącym oddziale onkologii

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Dr Zalmanova specjalizuje się w radioterapii, ze szczególnym uwzględnieniem gruczolakoraka w Centrum Medycznym Assuta.

• Radioterapeuta z doświadczeniem w celowanym leczeniu promieniowaniem
• Pracuje w Centrum Medycznym Assuta, znanym z zaawansowanej opieki onkologicznej
• Koncentruje się na spersonalizowanych planach leczenia dla pacjentów z gruczolakorakiem